What's new

Human medicines European public assessment report (EPAR): Epruvy (previously Ranibizumab Midas), ranibizumab, Date of authorisation: 19/09/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Epruvy (previously Ranibizumab Midas), ranibizumab, Date of authorisation: 19/09/2024, Revision: 2, Status: Authorised

May 27, 2025 - 09:35
 0
Human medicines European public assessment report (EPAR): Epruvy (previously Ranibizumab Midas), ranibizumab, Date of authorisation: 19/09/2024, Revision: 2, Status: Authorised
Human medicines European public assessment report (EPAR): Epruvy (previously Ranibizumab Midas), ranibizumab, Date of authorisation: 19/09/2024, Revision: 2, Status: Authorised
Read More

Tags:

Previous Article

STAT+: At a major genome editing summit, spotlight turns to the value of human life

Next Article

Secretary General thanks NATO parliamentarians for key role in strengthening the...

Related Posts

Human medicines European public assessment report (EPAR): Arexvy, recombinant respiratory syncytial virus pre-fusion F protein, adjuvanted with AS01E, Date of authorisation: 06/06/2023, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR...

May 27, 2025  0

Human medicines European public assessment report (EPAR): Inhixa, enoxaparin sodium, Date of authorisation: 15/09/2016, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR...

May 23, 2025  0

Veterinary medicines European public assessment report (EPAR): Innovax-ND-IBD-ILT, Avian infectious laryngotracheitis, infectious bursal disease, Marek’s disease and Newcastle disease vaccine (live recombinant), Status: Opinion

Veterinary medicines European public assessment report ...

May 16, 2025  0